Research & Education
CURE Expert Connections
CURE Speaking Out
Email Sign Up
To start your customized experience click the start button
Customize your homepage by selecting specific cancer types.
See all >
Acute Myeloid Leukemia
Cancer of Unknown Primary
Diet and Exercise
Gastrointestinal stromal tumor
General Financial Topics
General Psychosocial Aspect Topics
Head & Neck Cancer
Mantle Cell Lymphoma
Metastatic Breast Cancer
Side Effect Management
Small Lymphocytic Lymphoma (SLL)
Advocacy & Research
Share Your Story
Newsletter Sign Up
See all >
AWARD PROGRAM: Extraordinary Healer
AWARD PROGRAM: Ovarian Cancer Heroes
EDUCATED PATIENT SUMMIT: Lung Cancer
AWARD PROGRAM: Lung Cancer Heroes
Ovarian Cancer Heroes
Bone Health Champions
Terms & Conditions
Cure Media Group, LLC.
2 Clarke Drive
Cranbury, NJ 08512
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Paradise Awaits, One Day At a Time
I'm keeping hope alive that eventually, we'll get through the other side of the COVID-19 pandemic. One day at a time like anything else.
'Yet' Makes All the Difference
It's pretty clear that I have a lot of work ahead of me after years of devastation from cancer, but lately, I'm taking a new approach.
What You Need to Know About the FDA's Approval of Tazverik For Epithelioid Sarcoma
Patients with epithelioid sarcoma finally have a specific treatment after the FDA granted accelerated approval to Tazverik, providing new hope for the future of these patients.
FDA Approves Tazverik For Epithelioid Sarcoma
The Food and Drug Administration approved Tazverik for the treatment of patients with metastatic or locally advanced epithelioid sarcoma — marking the first treatment option specifically for these patients.
With a Little Help from My Friends
Having loved ones by your side is right up there in importance with any aspect of healing from cancer.
All the Answers
Thoughts on New Year's resolutions and planning for the years ahead when your future is tied up in uncertainty because of cancer.
Friday Frontline: Cancer Updates, Research and Education on December 20, 2019
From a newly proposed rule to help lower prescription drug prices to an oncology nurse and a patient with cancer singing “O Holy Night,” here’s what is making headlines in the cancer space this week.
Triumph Over Cancer: Riding 'Coast 2 Coast'
Kristie L. Kahl
Now a 10-year survivor of bone cancer, Dana Vaughns chose to triumph over his disease and joined Bristol-Myers Squibb on its Coast 2 Coast 4 Cancer ride.
Ten-Year Bone Cancer Survivor Rides 'Coast 2 Coast'
Kristie L. Kahl
Dana Vaughns and his colleagues rode 3,000 miles across the U.S. in support of funding research for the V Foundation.
Studying Rare Diseases Is Difficult, But Innovation Drives Results
Debu Tripathy, M.D.
Where does hope lie when it comes to improving the treatment landscape for rare cancers?
Not a member?
Sign up now!
Continue without login